This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Response Genetics, Inc. Reports Third Quarter Financial Results And Operational Update

Response Genetics Inc. (Nasdaq: RGDX) ("Response Genetics" or the "Company"), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results and business progress for the third quarter ended September 30, 2011.

“Sales and revenue of our ResponseDX™ genetic tests continue to increase with a record number of tests ordered during this quarter, and with the addition of seven new sales staff is expected to increase further,” said Denise McNairn, Interim CEO of Response Genetics. “In addition, as we expand our testing services globally and refine our internal systems we will continue to bring value to our stockholders and benefits to physicians and their patients.”

Third Quarter 2011 Financial Results

Total revenue decreased by 9 percent to $5.1 million for the third quarter ended September 30, 2011, compared to $5.6 million for the same period last year. The decrease was primarily due to a decrease in pharmaceutical service revenue of $0.8 million, offset by an increase of $0.3 million in ResponseDX™ revenue. Revenue from ResponseDX™ genetic tests increased by 10 percent to $3.3 million for the third quarter, compared to $3.0 million for the same period in 2010. Pharmaceutical client revenue decreased 30.7 percent to $1.8 million, compared to $2.6 million in the third quarter of 2010.

Cost of revenue was $2.5 million for the third quarter ended September 30, 2011, compared with $2.7 million for the same period in 2010. Research and development expenses were $0.5 million for the third quarter of 2011, compared with $0.3 million for the same period in 2010. General and administrative expenses were $2.3 million for the third quarter, compared with $2.0 million for the same period in 2010. Selling and marketing expenses were $1.3 million for the third quarter of 2011, compared with $1.6 million for the same period in 2010. Total operating expenses for the third quarter were $6.5 million, compared with $6.6 million for the same period last year. The decrease in total operating expenses was related to a reduction in sales personnel expenses, offset by an increase in business consulting and personnel recruiting expenses. Stock compensation expense was $0.2 million for the third quarter of 2011, compared to $0.3 million for the same period in 2010.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs